Dose-Dependent Anti-Fibrotic Effect of Thymoquinone on Renal TGF-β1 Expression in Wistar Rats with Unilateral Ureteral Obstruction
DOI:
https://doi.org/10.37275/bsm.v10i7.1626Keywords:
Chronic kidney disease, Renal fibrosis, TGF-β1, Thymoquinone, Unilateral ureteral obstructionAbstract
Background: Renal fibrosis is the final common pathway of chronic kidney disease (CKD), regulated by the pro-fibrotic cytokine Transforming Growth Factor-β1 (TGF-β1). Thymoquinone, the principal bioactive constituent of Nigella sativa, has antioxidant, anti-inflammatory and anti-fibrotic activity in pre-clinical models, but its dose-response profile in obstructive nephropathy is incompletely characterised.
Methods: This in-vivo experimental study used a post-test-only with control-group design in 30 male Wistar rats (200–250 g) randomised into six groups (n=5): sham + olive-oil; UUO + olive-oil; UUO without olive-oil; and UUO with intra-peritoneal thymoquinone at 5, 10 or 20 mg/kg body-weight daily for 14 days. The primary outcome was renal cortical TGF-β1 mRNA expression by RT-PCR; secondary outcomes were IL-6 expression, serum urea and creatinine, Sirius-red percentage of positively-stained area (PSA) and a PAS-stained tubular injury score.
Results: UUO produced renal injury: urea rose from 41.3 ± 6.2 to 57.7 ± 7.6 mg/dL (p=0.003) and TGF-β1 expression rose from 473,500 ± 32,797 to 679,922 ± 27,998 densitometric units (p=0.001). Thymoquinone reduced TGF-β1 dose-dependently to 644,571 ± 25,457, 612,143 ± 23,822 and 581,571 ± 24,128 a.u. at 5, 10 and 20 mg/kg (ANOVA p=0.004); the 20 mg/kg dose was superior to lower doses (p<0.05). PSA and tubular injury improved in parallel and correlated strongly with TGF-β1 (r=0.85).
Conclusion: Thymoquinone exerts a dose-dependent anti-fibrotic effect via TGF-β1 down-regulation in obstructive nephropathy, supporting its evaluation as a complementary anti-fibrotic adjunct in CKD.
Authors
- M Zulfikar Abadi1*
- Suprapti1
- Muhammad Irsan Saleh2
- Zulkhair Ali1
- Novadian1
- 1Division of Nephrology and Hypertension, Department of Internal Medicine, Dr. Mohammad Hoesin General Hospital/Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
- 2Division of Biomedics, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
Corresponding author M Zulfikar Abadi — zulfikarabadi20@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
